Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial

Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial

A randomized, double-blind, controlled phase 3 trial was conducted during a COVID-19 outbreak after the initial, stringent zero-Covid policy was relaxed in three provinces. Eligible adults aged ≥18 years who had received three doses of inactivated COVID-19 vaccines 6 months earlier were randomly ass...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao-Qiang Liu, Yang-Yang Qi, Tao Huang, Li-Li Huang, Ming-Xuan Zhao, Zhong-Fang Wang, Jun Dai, Yan-Xia Wang, Jing-Jing Chen, Xiao-Yun Yang, Hui-Lan Fan, Xue-Mei Yan, Jian-Chang He, Yan-Xiang Zou, Zhi-Wei Jiang, Zhi-Fei Zhan, Si-Wen Tao, De-Fang Dai, Feng Shi, Qiong-Na Zhang, Xiu-Liang Yang, Xiao-Zhong Li, Wei Li, Jing Lu, Jiang-Bing Zheng, Zhi-Hua Zhang, Gao-Xiang Chen, Hong Su, Wei-Min Gao, Lorenz von Seidlein, Xuan-Yi Wang, Lin Yuan, Jin-Zhong Lin
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Efficacy
safety
mRNA vaccine
COVID-19
chimeric
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2502250
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items